Global Cell Therapy Biomanufacturing Market Projected to Reach $16.7 Billion by 2029

Revolutionizing Cell Therapy Biomanufacturing: Advanced Technologies Enhance Efficiency, Scalability, and Affordability, Paving the Way for Broader Patient Access

BOSTON, Sept. 24, 2024 /PRNewswire/ — “According to the latest BCC Research study, the demand for “Cell Therapy Biomanufacturing: Global Markets” is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2024 to 2029.”

The global cell therapy biomanufacturing market is currently experiencing dynamic shifts driven by significant R&D investments, intensified competition among industry players, and the rapid emergence of innovative technologies. These factors are pivotal in shaping market growth trajectories while offering valuable insights for stakeholders and potential entrants alike. The landscape is further influenced by ongoing advancements and frequent product launches, bolstered by supportive governmental initiatives. Corporate strategies such as mergers, acquisitions, and partnerships play a crucial role in navigating this evolving terrain, optimizing operational efficiencies, and meeting evolving consumer demands in the biomanufacturing sector.

This report is especially relevant at this moment, as the cell therapy field is undergoing rapid expansion and innovation. With an increasing number of therapies advancing through clinical development and achieving regulatory approvals, the demand for efficient and scalable cell-based treatments is escalating. This surge in demand highlights the critical need to optimize biomanufacturing processes to meet market expectations while ensuring high quality and safety standards. Advances in biotechnology, automation, and data-driven analytics are playing a transformative role in this space, enabling significant improvements in productivity, cost-efficiency, and scalability of cell therapy manufacturing. These technological advancements not only enhance the ability to produce therapies at a larger scale but also pave the way for more consistent and reliable manufacturing outcomes. As the industry continues to evolve, this report provides timely insights into how these emerging technologies can be leveraged to address current challenges, capitalize on new opportunities, and maintain a competitive edge in the rapidly growing cell therapy market.

Please click here for more details on “The global market for cell therapy biomanufacturing Report.”

The following factors drive the global market for cell therapy biomanufacturing:

Rising Prevalence of Chronic and Degenerative Diseases: The increasing incidence of chronic conditions like cancer, diabetes, and cardiovascular diseases is driving demand for innovative treatments, such as cell therapy. These diseases require long-term management, and cell therapies offer potential cures or significant improvements, thus fueling the need for advanced biomanufacturing processes.

Technological Advancements in Bioprocessing: Innovations in bioprocessing are enhancing the efficiency, scalability, and cost-effectiveness of cell therapy production. Advances in automation, single-use technologies, and bioreactor design are streamlining manufacturing, reducing contamination risks, and improving product consistency, which is essential for meeting the growing demand for quality cell therapies.

Growing Investment in Research and Development (R&D): Investment in R&D from both public and private sectors is on the rise, driving the discovery of new cell therapies and improving existing ones. This increased funding supports innovative biomanufacturing techniques and the establishment of regulatory frameworks, which are crucial for the growth of the cell therapy market.

Expansion of Cell Therapy Manufacturing Infrastructure: To support large-scale cell therapy production, the expansion of manufacturing infrastructure is essential. This includes developing specialized facilities, adopting advanced technologies, and establishing robust supply chains. Enhanced infrastructure ensures that cell therapies can be produced at the necessary scale and quality to meet market demands.

Request a sample copy of the global market for cell therapy biomanufacturing reports.

Report Synopsis

Key Interesting Facts About the global market for cell therapy biomanufacturing:

3D Bioprinting of Tissues and Organs:

Revolutionizing Tissue Engineering: 3D bioprinting enables the precise creation of complex tissues using living cells and biomaterials.Customized Constructs: Potential to fabricate tissues for transplantation, drug testing, and disease modeling.Advancing Regenerative Medicine: Plays a critical role in cell therapy biomanufacturing by enabling more tailored treatment options.

Expansion of Allogeneic Cell Therapies:

Off-the-Shelf Solutions: Allogeneic therapies use cells from healthy donors, offering scalability and cost-effectiveness.Increased Accessibility: More accessible compared to autologous therapies, which require individualized cell processing.Biomanufacturing Momentum: Gaining traction as a promising approach in cell therapy biomanufacturing.

The global market for cell therapy biomanufacturing report includes in-depth data and analysis addressing the following important queries:

What is the projected market size and growth rate of the cell therapy biomanufacturing global market?
The market is projected to grow from $8.6 billion in 2023 and is expected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period.

What segments are covered in the market?
The cell therapy biomanufacturing market is segmented based on product type, application, and region.

By product type, which segment will dominate the market by 2029?
By product type, the type of therapy is anticipated to contribute the highest share in the market by the end of 2029.

Which application market is growing fastest among all?
Cancer is the fastest growing market.

Some of the Key Market Players Are:

BIOSENICBRISTOL-MYERS SQUIBB CO.DANAHER CORP.IOVANCE BIOTHERAPEUTICS INC.LISATA THERAPEUTICSLONZAMERCK KGAATHERMO FISHER SCIENTIFIC INC.

Browse Related Reports

Biologics Development and Manufacturing Testing: Technologies and Global Markets: This report provides a comprehensive analysis of the global biologic’s safety testing market, combining quantitative and qualitative data to support business strategy development. It covers biosafety testing of raw materials, cell banks, virus seeds, and drug substances/products, and segments the market by application, testing technology, and region. The report examines industry growth drivers, trends, opportunities, and regulatory environments, alongside market projections and competitive landscape insights. Additionally, it includes company profiles and evaluates the impact of COVID-19 on the biologic’s safety testing market.

Directly Purchase a copy of the report with BCC Research.

For further information or to make a purchase, please get in touch with [email protected].

About BCC Research

BCC Research provides objective, unbiased measurement, and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.

Contact Us

Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA

Email: [email protected],

Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo – https://mma.prnewswire.com/media/2183242/4931363/BCC_Research_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/global-cell-therapy-biomanufacturing-market-projected-to-reach-16-7-billion-by-2029–302257609.html

SOURCE BCC Research LLC